Using serum pepsinogens wisely in a clinical practice

Journal of Digestive Diseases

Volumn 8, Issue 1, 2007, Pages 8-14

  Miki, Kazumasa ^a   Urita, Yoshihisa ^a  

^a TOHO UNIVERSITY   (Japan)

Author keywords

Atrophic gastritis; Gastric cancer screening; Non atrophic gastritis; Serum pepsinogens I and II.

Indexed keywords

EID: 84876033255     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1443-9573.2007.00278.x     Document Type: Article

References (70)

1. Huang SC, Miki K, Sano J et al. Pepsinogens I and II in gastric cancer: an immunohistochemical study using monoclonal antibodies. Jpn J Cancer Res 1988; 79: 1139-46.
2. Samloff IM. Cellular localization of group I pepsinogens in human gastric mucosa by immunofluorescence. Gastroenterology 1971; 61: 185-8.
3. Samloff IM, Liebman WM. Cellular localization of the group II pepsinogens in human stomach and duodenum by immunofluorescence. Gastroenterology 1973; 65: 36-42.
4. Miki K, Ichinose M, Shimizu A et al. Serum pepsinogens as a screening test of extensive chronic gastritis. Gastroenterol Jpn 1987; 22: 133-41.
5. Miki K, Ichinose M, Ishikawa KB et al. Clinical application of serum pepsingen I and II levels for mass screening to detect gastric cancers. Jpn J Cancer Res 1993; 84: 1086-90.
6. Ichinose M, Yahagi N, Oka M et al. Screening for gastric cancer in Japan. In: Wu GY, Aziz K, eds. Cancer Screening Practical Guide for Physicians. Totowa, NY: Humana Press, 2001, pp. 255-68.
7. Calam J, Gibbons A, Healey ZV et al. How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology. Gastroenterology 1997; 113 (Suppl.): S43-9.
8. Collen MJ, Lewis JH, Benjamin SB. Gastric acid hypersecretion in refractory gastroesophageal reflux disease. Gastroenterology 1990; 98: 654-61.
9. Zhu H, Pace F, Sangaletti O et al. Gastric acid secretion and pattern of gastroesophageal reflux in patients with esophagitis and concomitant duodenal ulcer. A multivariate analysis of pathogenetic factors. Scand J Gastroenterol 1993; 28: 387-92.
10. Carlborg L, Dahlgren S, Nordgren B. Gastric secretion of hydrochloric acid and sialic acid in patients with peptic ulcer and gastric cancer during intravenous infusion of histamine. Scand J Gastroenterol 1970; 5: 427-31.
11. Kobayashi S, Kizu M, Kasugai T. Gastric acid secretion in relation to gross type of gastric cancer. Am J Gastroenterol 1973; 60: 366-71.
12. Konturek SJ, Starzynska T, Konturek PC et al. Helicobacter pylori and CagA status, serum gastrin, interleukin-8 and gastric acid secretion in gastric cancer. Scand J Gastroenterol 2002; 37: 891-8.
13. Samloff IM, Liebman WM, Panitch NM. Serum group 1 pepsinogens by radioimmunoassay in control subjects and patients with peptic ulcer. Gastroenterology 1975; 69: 83-90.
14. Feldman M, Richardson CT, Lam SK et al. Comparison of gastric acid secretion rates and serum pepsinogen 1 and 2 concentrations in accidental and oriental duodenal ulcer patients. Gastroenterology 1998; 95: 630-5.
15. Haruma K, Yoshihara M, Sumii K et al. Gastric acid secretion, serum pepsinogen 1, and serum gastrin in Japanese with gastric hyperplastic polyps or polypoid-type early gastric carcinoma. Scand J Gastroenterol 1993; 28: 633-7.
16. Kinoshita Y, Kawanami C, Kishi K et al. Helicobacter pylori-independent chronological change in gastric acid secretion in the Japanese. Gut 1997; 41: 452-8.
17. Yasunaga Y, Shinomura Y, Kanayama S et al. Serum pepsinogen 1 levels and acid secretion in Helicobacter pylori associated enlarged fold gastritis. Itl J Gastroenterol 1995; 28: 457-61.
18. Iijima K, Sekine H, Koike T et al. Serum pepsinogen concentrations as a measure of gastric acid secretion in Helicobacter pylori-negative and -positive Japanese subjects. J Gastroenterol 2005; 40: 938-44.
19. Dooley CP, Cohen H, Fitzgibbsons PL et al. Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons. N Engl J Med 1989; 321: 1562-6.
20. Graham DY. Campylobacter pylori and peptic ulcer disease. Gastroenterology 1989; 96 (Suppl.): 615-25.
21. Wagner S, Haruma K, Gladziwa U et al. Helicobacter pylori infection and serum pepsinogen A, pepsinogen C, and gastrin in gastritis and peptic ulcer: significance of inflammation and effect of bacterial eradication. Am J Gastroenterol 1994; 89: 1211-8.
22. Asaka M, Kimura T, Kudo M et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology 1992; 102: 760-6.
23. Chen TS, Lee YC, Li FY et al. Smoking and hyperpepsinogenemia are associated with increased risk for duodenal ulcer in Helicobacter pylori-infected patients. J Clin Gastroenterol 2005; 39: 699-703.
24. Biasco G, Paganelli GM, Varia D et al. Serum pepsinogen 1 and 2 concentrations and IgG antibody to Helicobacter pylori in dyspeptic patients. J Clin Pathol 1993; 46: 826-8.
25. Kuipers EJ, Pals G, Pena AS et al. Helicobacter pylori, pepsinogens and gastrin: relationship with age and development of atrophic gastritis. Eur J Gastroenterol Hepatol 1996; 8: 153-6.
26. Hunter FM, Correa P, Fonthan E et al. Serum pepsinogens as markers of response to therapy for Helicobacter pylori gastritis. Dig Dis Sci 1993; 38: 81-6.
27. Cave TR, Cave DR. Helicobacter pylori stimulates pepsin secretion from isolated rabbit gastric glands. Scand J Gastroenterol 1991; 181: 9-14.
28. Young GO, Stemmet N, Lastovica A et al. Helicobacter pylori lipopolysaccharide stimulates gastric mucosal pepsinogen secretion. Aliment Pharmacol Ther 1992; 6: 169-77.
29. Lorente S, Doiz O, Serrano MT et al. Helicobacter pylori stimulates pepsinogen secretion from isolated human peptic cells. Gut 2002; 50: 13-8.
30. Ohkusa T, Takashimizu I, Fujiki K et al. Changes in serum pepsinogen, gastrin, and immunoglobulin G antibody titers in Helicobacter pylori-positive gastric ulcer after eradication of infection. J Clin Gastroenterol 1997; 25: 317-22.
31. Rauws EAJ, Langenberg W, Houthoff HJ et al. Campylobacter pyloridis-associated chronic active gastritis. A prospective study of its prevalence and the effects of antibacterial and anti-ulcer treatment. Gastroenterology 1988; 94: 33-40.
32. Di Mario F, Moussa AM, Cavallaro LG et al. Clinical usefulness of serum pepsinogen 2 in the management of Helicobacter pylori infection. Digestion 2004; 70: 167-72.
33. Gisbert JP, Boixeda D, Al-Mostafa A et al. Basal and stimulated gastrin and pepsinogen levels after eradication of Helicobacter pylori: a 1-year follow-up study. Eur J Gastroenterol Hepatol 1999; 11: 189-200.
34. Furuta T, Kaneko E, Baba S et al. Percentage changes in serum pepsinogens are useful as indices of eradication of Helicobacter pylori. Am J Gastroenterol 1997; 92: 84-8.
35. Mirvishi SS. The etiology of gastric cancer. J Natl Cancer Inst 1983; 71: 629-47.
36. Komoto K, Haruma K, Kamada T et al. Helicobacter pylori infection and gastric neoplasia: correlations with histological gastritis and tumor histology. Am J Gastroenterol 1998; 93: 1271-6.
37. Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol 1995; 19: S37-S43.
38. Sipponen P, Kekki M, Haapakoski J et al. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer 1985; 35: 173-7.
39. Xia HHX, Kalantar JS, Talley NJ et al. Antral-type mucosa in the gastric incisura, body, and fundus (antralization): a link between Helicobacter pylori infection and intestinal metaplasia? Am J Gastroenterol 2000; 95: 114-21.
40. Urita Y, Hike K, Torii N et al. Serum pepsinogens as a predicator of the topography of intestinal metaplasia in patients with atrophic gastritis. Dig Dis Sci 2004;49:795-801
41. Shirin H, Bruck R, Kenet G et al. Evaluation of a new immunochromatographic test for Helicobacter pylori IgG antibodies in elderly symptomatic patients. J Gastroenterol 1999; 34: 7-10.
42. Newell DG, Hawtin PR, Stacey AR et al. Estimation of prevalence of H. pylori infection in an asymptomatic elderly population comparing [14C] urea breath test and serology. J Clin Pathol 1991; 44: 385-7.
43. Miki K, Ichinose M, Kakei N et al. The clinical application of the serum pepsinogen I and II levels as a mass screening method for gastric cancer. In: Takahashi K, ed. Aspartic Proteinases: Structure, Function, Biology and Biomedical Implications. New York: Plenum Press, 1995; 139-43.
44. Kodori A, Yoshihra M, Sumii K et al. Serum pepsinogen in screening for gastric cancer. J Gastroenterol 1995; 30: 452-60.
45. Kitahara F, Kobayashi K, Sato T et al. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut 1999; 44: 693-7.
46. Nishizawa Y. Investigation of mass survey for gastric cancer. J Gastroenterol Mass Survey 1993; 98: 74-9 (in Japanese).
47. Miki K. Gastric cancer screening using serum tests (stomach dry dock). Study of the systems of the first screening for cancer-susceptible subjects by serum pepsinogen levels and the secondary close-examination by every-other-year panendoscopy. J Gastroenterol Mass Survey 1994; 32: 19-30 (in Japanese).
48. Oksanen A, Sipponen P, Miettinen A et al. Evaluation of blood tests to predict normal gastric mucosa. Scand J Gastroenterol 2000; 35: 791-5.
49. Biemond I, Kreuning J, Jansen JB et al. Serum pepsinogens in patients with gastric diseases or after gastric surgery. Scand J Gastroenterol 1994; 29: 238-42.
50. Dinis-Ribeiro M, Yamaki G, Miki K et al. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen 2004; 11: 141-7.
51. Hattori Y, Tashiro H, Kawamoto T et al. Sensitivity and specificity of mass screening for gastric cancer using the measurement of serum pepsinogens. Jpn J Cancer Res 1995; 86: 1210-5.
52. Hanai A, Tsukuma H, Hiyama T et al. Cancer survival in Osaka. In: Tominaga S, Aoki K, Fujimoto I et al., eds. Cancer Mortality and Morbidity Statistics. Ann Arbor, MI: CRC Press, 1994; 159-65.
53. Gorey KM, Holowaty EJ, Fehringer G et al. An international comparison of cancer survival: Toronto, Ontario, and Detroit, Michigan, metropolitan areas. Am J Public Health 1997; 87: 1156-63.
54. Tsubono Y, Hisamichi S. Screening for gastric cancer in Japan. Gastric Cancer 2000; 3: 9-18.
55. Murakami R, Tsukuma H, Ubukata T et al. Estimation of validity of mass screening program for gastric cancer in Osaka, Japan. Cancer 1990; 65: 1255-60.
56. Fukao A, Hisamichi S, Takano A et al. Accuracies of mass screening for gastric cancer-test sensitivity and program sensitivity. J Gastroenterol Mass Survey 1992; 97: 59-63. (in Japanese).
57. Hosakawa O. Transition in the diagnostic methods for gastric cancer and screening for gastric cancer. J Gastroenterol Mass Survey 1995; 33: 195-9 (in Japanese).
58. Waye JD, Abakken L, Armengol-Miro JR et al. Screening for GI cancer and payment mechanisms. Gastrointest Endosc 2002; 55: 453-4.
59. Dan YY, So BJ, Yeoh KG. Endoscopic screening for gastric cancer. Clin Gastroenterol Hepatol 2006; 4: 709-16.
60. Hosokawa O, Hattori M, Takeda T et al. Accuracy of endoscopy in detecting gastric cancer. Jpn J Gastroenterol Mass Survey 2004; 42: 33-9 (in Japanese).
61. Nishizawa M, Nomoto K, Hosoi T et al. The diagnostic precision of routine panendoscopy in the detection of early cancer of the stomach. I to Cho 1985; 20: 949-54 (in Japanese).
62. Ministry of Health, Labour and Welfare. Vital Statistics of Japan, Statistics and Information, vol. 1. Tokyo: Minister's Secretariat, Ministry of Health, Labour and Welfare, 2002 (in Japanese).
63. Koga M, Miyakawa K, Ikeda S. Annual Report of Gastroenterological Mass Survey in Japan, 2002. Tokyo: Japanese Society of Gastroenterology Mass Survey, 2004 (in Japanese).
64. Yoshihara M, Sumii K, Haruma K et al. The usefulness of gastric mass screening using serum pepsinogen levels compared with photofluorography. Hiroshima J Med Sci 1997; 46: 81-6.
65. Morrison AS. Screening in Chronic Disease, 2nd edn. New York: Oxford University Press, 1992.
66. Ohata H, Oka M, Yanaoka K et al. Gastric cancer screening of a high-risk population in Japan using serum pepsinogen and barium digital radiography. Cancer Sci 2005; 96: 713-20.
67. Kikuchi S, Wada O, Nakajima T et al. Serum anti-Helicobacter pylori antibody and gastric carcinoma among young adults. Research Group on Prevention of Gastric Carcinoma among Young Adults. Cancer 1995; 75: 2789-93.
68. Kikuchi S, Yagyu K, Obata Y et al. Serum pepsinogen values and Helicobacter pylori status among control subjects of a nested case-control study in the JACC study. J Epidemiol 2005; 15 (Suppl.): S126-33.
69. Blaser MJ, Chyou PH, Nomura A. Age at establishment of Helicobacter pylori infection and gastric carcinoma, gastric ulcer, and duodenal ulcer risk. Cancer Res 1995; 55: 562-5.
70. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major caners in 1990. Int J Cancer 1999; 80: 827-41.